Home Alzheimer’s Disease Cemiplimab Shows Promise for Patients with Advanced Basal Cell Carcinoma

Cemiplimab Shows Promise for Patients with Advanced Basal Cell Carcinoma

Topline data from the pivotal, single-arm, open-label trial of cemiplimab (Libtayo) in patients with advanced basal cell carcinoma (BCC) who had progress on or were intolerant to prior hedgehog pathway inhibitor (HHI) therapy were announced by Sanofi and Regeneron, the developers of the PD-1 inhibitor. 

Cemiplimab showed clinically meaningful and durable responses in this group of patients for whom there are no currently approved treatments. The companies indicated that they anticipate regulatory submissions sometime in 2020.

BCC is the second non-melanoma skin cancer for which cemiplimab has demonstrated first-in-class data, as the agent was initially approved in the US, EU, and other countries for advanced cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. 

“While PD-1 inhibitors have transformed…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Recent Comments